Search

ENPNewswire-October 23, 2023--Lilly's Retevmo Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented [...]

ENPNewswire-October 10, 2023--Foundation Medicine Inc. - U.S. Food and Drug Administration Approves FoundationOneCDx as a Companion Diagnostic for Lilly's Retevmo for Certain Patients with Solid Tumors (C)2023 ENPublishing - http://www.enpublishing.co.uk [...]

ENPNewswire-October 9, 2023--Lilly Announces Details of Presentations at ESMO Congress 2023 (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 06102023 - INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) today announced that [...]

ENPNewswire-April 28, 2021--Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance (C)2021 ENPublishing - http://www.enpublishing.co.uk Release date- 27042021 - INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) announced financial [...]

ENPNewswire-March 11, 2021--Eli Lilly and Company - Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (C)2021 ENPublishing - http://www.enpublishing.co.uk Release date- 10032021 - INDIANAPOLIS - Eli [...]

ENPNewswire-August 28, 2020--Eli Lilly and Company - New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo in Advanced RET-Driven Lung and Thyroid Cancers (C)2020 ENPublishing - http://www.enpublishing.co.uk Release [...]